Eli Lilly, a pharmaceutical company, has partnered with OpenAI to develop novel antimicrobials to combat drug-resistant pathogens. This collaboration aims to address the global threat of antimicrobial resistance, leveraging generative AI technology.
Lilly becomes the latest pharma to tap OpenAI for help, this time for antibiotic work https://t.co/7B2sVu7m5b
🇺🇸OPENAI GETS INTO THE DRUG BUSINESS... BIG PHARMA PARTNERSHIP What could go wrong? The deal will allow Lilly to leverage generative AI in developing antimicrobials for drug-resistant bacteria. They hope to create new treatments for superbugs, which cause over 2.8 million… https://t.co/KItoFO7pwR
Quick Takes: AI for antibiotic discovery, bedaquiline gets traditional approval, oral antifungal shows promise Eli Lilly says it will use OpenAI's generative AI to discover novel new antimicrobials. https://t.co/V5wRJOcLVY
Definitely intrigued... Eli Lilly inks OpenAI deal for discovering new antibiotics https://t.co/YbTIvH9rJX
“Lilly collaborates with @OpenAI to discover novel medicines to treat drug-resistant bacteria” https://t.co/B4MYrLBfED
Lilly becomes the latest pharma to tap OpenAI for help, this time for antibiotic work - https://t.co/Cp1JjleMGR
Eli Lilly said on Tuesday it will collaborate with OpenAI to leverage its generative AI to develop antimicrobials that can be used to treat drug-resistant bacteria. https://t.co/ts2oZ164PY https://t.co/ts2oZ164PY
Eli Lilly is teaming up with OpenAI on a quest to develop new treatments for overcoming antimicrobial resistance. $LLY https://t.co/yeka82qO5X
Lilly's press release also mentioned that the "collaboration with OpenAI supports Lilly's earlier commitment to fighting drug-resistant pathogens through its Social Impact Venture Capital Portfolio." Lilly's Social Impact Venture Capital Portfolio includes the @AMRActionFund https://t.co/FTI6TnEKk0
Dave Ricks/Lilly CEO: "Our collaboration with OpenAI is a step forward in the important fight against antimicrobial resistance. We look forward to combining the power of our scientists with OpenAI’s platform & engineers to take on this challenging—and critical—need in global… https://t.co/FTI6TnFi9y
"Generative AI opens a new opportunity to accelerate the discovery of novel antimicrobials & the development of custom, purpose-built technologies in the battle against drug-resistant pathogens," said Diogo Rau @diogorau, EVP & chief information and digital officer at $LLY https://t.co/FTI6TnFi9y
Eli Lilly & CEO Dave Ricks announced a collaboration with @OpenAI to leverage generative AI to invent novel antimicrobials to treat drug-resistant pathogens. Antimicrobial resistance (AMR) is 1 of the top public health & development threats globally https://t.co/WAQoTymQ7O $LLY
Lilly, $LLY, partners with OpenAI to develop medicines for drug-resistant bacteria